Subcellular MLH1 protein as first in class biomarker for CDK4/6 response in endocrine resistant ER+/HER2-breast cancer

被引：0
|
作者：
Mazumder, Aloran
Oropeza, Elena
Punturi, Nindo
Haricharan, Svasti
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-5129
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5129
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
    Mai, Nicholas
    dos Anjos, Carlos H.
    Razavi, Pedram
    Safonov, Anton
    Patil, Sujata
    Chen, Yuan
    Drago, Joshua Z.
    Modi, Shanu
    Bromberg, Jacqueline F.
    Dang, Chau T.
    Liu, Dazhi
    Norton, Larry
    Robson, Mark
    Chandarlapaty, Sarat
    Jhaveri, Komal
    NPJ BREAST CANCER, 2024, 10 (01)
  • [22] Early metabolic response assessment to neoadjuvant endocrine treatment in ER+, HER2-breast cancer: comparison to the morphological and pathological response
    Boughdad, Sarah
    Champion, Laurence
    Becette, Veronique
    Cherel, Pascal
    Mouret-Fourme, Emmanuelle
    Edeline, Veronique
    Lemonnier, Jerome
    Lerebours, Florence
    Alberini, Jean-Louis
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (03)
  • [23] Prediction of CDK inhibitor efficacy in ER+/HER2-breast cancer using machine learning algorithms
    Mason, Jeremy
    Gong, Yutao
    Amiri-Kordestani, Laleh
    Wedam, Suparna
    Gao, Jennifer J.
    Singh, Harpreet
    Pazdur, Richard
    Kuhn, Peter
    Blumenthal, Gideon
    Beaver, Julia A.
    CANCER RESEARCH, 2020, 80 (04)
  • [24] Resistance Mechanisms to Combined CDK4/6 Inhibitors and Endocrine Therapy in ER+/HER2-Advanced Breast Cancer: Biomarkers and Potential Novel Treatment Strategies
    Al-Qasem, Abeer J.
    Alves, Carla L.
    Ditzel, Henrik J.
    CANCERS, 2021, 13 (21)
  • [25] The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2-Breast Cancer
    Oshi, Masanori
    Takahashi, Hideo
    Tokumaru, Yoshihisa
    Yan, Li
    Rashid, Omar M.
    Nagahashi, Masayuki
    Matsuyama, Ryusei
    Endo, Itaru
    Takabe, Kazuaki
    CELLS, 2020, 9 (07) : 1 - 19
  • [26] Targeting of endocrine therapy-induced estrogen-receptor/HER2-cross-talk in circulating tumor cells from metastatic ER+/HER2-breast cancer: Implications for treatment of ER+/HER2-breast cancer
    Thaler, S.
    Rosswag, S.
    Pantel, K.
    Sleeman, J. P.
    Schmidt, M.
    Cotarelo, C. L.
    CANCER RESEARCH, 2019, 79 (04)
  • [27] SPEN is a biomarker for CDK4/6 inhibitor resistance in patients with metastatic hormone receptor positive (HR+)/HER2-breast cancer
    Van Geelen, Courtney T.
    Teo, Zhi Ling
    Savas, Peter
    Luen, Stephen J.
    Clarke, Kylie A.
    Sant, Sneha
    Cowley, Karla J.
    Caramia, Franco
    Simpson, Kaylene J.
    Andre, Fabrice
    Dawson, Sarah-Jane
    Pearson, Richard
    Loi, Sherene
    CANCER RESEARCH, 2023, 83 (05)
  • [28] Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
    Luigi Formisano
    Yao Lu
    Alberto Servetto
    Ariella B. Hanker
    Valerie M. Jansen
    Joshua A. Bauer
    Dhivya R. Sudhan
    Angel L. Guerrero-Zotano
    Sarah Croessmann
    Yan Guo
    Paula Gonzalez Ericsson
    Kyung-min Lee
    Mellissa J. Nixon
    Luis J. Schwarz
    Melinda E. Sanders
    Teresa C. Dugger
    Marcelo Rocha Cruz
    Amir Behdad
    Massimo Cristofanilli
    Aditya Bardia
    Joyce O’Shaughnessy
    Rebecca J. Nagy
    Richard B. Lanman
    Nadia Solovieff
    Wei He
    Michelle Miller
    Fei Su
    Yu Shyr
    Ingrid A. Mayer
    Justin M. Balko
    Carlos L. Arteaga
    Nature Communications, 10
  • [29] Optimizing CDK4/6 inhibitors in advanced HR+/HER2-breast cancer: A personalized approach
    Fontanella, Caterina
    Giorgi, Carlo Alberto
    Russo, Stefania
    Angelini, Silvia
    Nicolardi, Linda
    Giarratano, Tommaso
    Frezzini, Simona
    Pestrin, Marta
    Palleschi, Dario
    Bolzonello, Silvia
    Parolin, Veronica
    Haspinger, Eva R.
    De Rossi, Costanza
    Greco, Filippo
    Gerratana, Lorenzo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 180
  • [30] Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer
    Stefania Belli
    Daniela Esposito
    Alessandra Allotta
    Alberto Servetto
    Paola Ciciola
    Ada Pesapane
    Claudia M. Ascione
    Fabiana Napolitano
    Concetta Di Mauro
    Elena Vigliar
    Antonino Iaccarino
    Carmine De Angelis
    Roberto Bianco
    Luigi Formisano
    npj Breast Cancer, 9
12345